Human Brain Organoid Models of Developmental Epilepsies

Vanesa Nieto-Estévez, PhD and Jenny Hsieh, PhD

1 Department of Biology and Brain Health Consortium, The University of Texas at San Antonio, TX, USA
*Correspondence: Jenny Hsieh, Department of Biology and Brain Health Consortium, The University of Texas at San Antonio, TX, USA; e-mail: jenny.hsieh@utsa.edu

Abstract
Epilepsy is a common neurological disorder characterized by recurrent and unprovoked seizures due to neuronal hyperactivity. A large proportion of epilepsy cases begin during childhood. Causes of epilepsy include stroke, infections, brain injury, genetic factors, or other factors that alter brain structure and development, but in up to 50% of cases the cause is unknown. Approximately 35% of patients have refractory seizures that do not respond to medication. Animal models and in vitro cultures have contributed to our understanding of epilepsy, but there is a clear need for better models to explore the human brain in normal and pathological conditions. Human pluripotent stem cell (PSC) technologies opened the door for new models for analyzing brain development and disease, especially conditions with a genetic component. Initially, PSCs were differentiated into 2-dimensional cultures of a homogenous population of neural cells, such as glutamatergic excitatory or γ-aminobutyric acidergic inhibitory neurons, as well as glial cells. Nevertheless, these cultures lacked the structure and complexity of a human brain. In the last decade, PSC technology has advanced to the next level through the development of 3-dimensional culture, called organoids. These organoids recapitulate features of the human brain that are missing in animal models, enabling a deeper study of the human brain. In this review, we will summarize the current status of organoid research and its application to epilepsy.

Keywords
induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), organoids, gene editing, epilepsy

Introduction
Epilepsy is a chronic neurological condition of recurrent and unprovoked seizures due to neuronal hyperactivity.1-3 It is a common disorder, affecting 65 million people around the world.4 Most cases manifest in childhood, reflecting the vulnerability of the developing brain, with an increasing proportion identified with genetic etiologies. More than 10 monogenic epilepsies have been modeled in vitro,5,6 using pluripotent stem cells (PSCs)—both embryonic stem cells (ESCs)7 and induced PSCs (iPSCs)8—that have been differentiated into neural cells.9-11 These methods have allowed mutations to be studied: iPSCs can be reprogrammed from a skin or blood sample from patients having epilepsy with a specific mutation and then differentiated in 2-dimensional (2D) cultures of glutamatergic excitatory or γ-aminobutyric acidergic inhibitory neurons, as well as glial cells (for a review of epilepsy 2D models see reference12,13). Likewise, specific mutations in patients with epilepsy can be introduced into ESCs or iPSCs derived from healthy controls by CRISPR-Cas9 gene editing and differentiated into neurons and glial cells using the same protocols.14 Moreover, gene editing can be used to correct mutations in patient iPSCs to obtain an isogenic control line with the same genetic background. However, these 2D cultures have limitations as human cell models of development and disease, because they lack the human brain’s cell–cell interaction, structure, complexity, and heterogeneity.15 More recently, the development of 3-dimensional (3D) culture, also called organoids, may have overcome some of these limitations, at least in part.16,17 In this review, we will summarize current brain-organoid protocols, highlight several examples of neurodevelopmental disorders that these models mimic, and
discuss the benefits and limitations of these models in uncovering epilepsy mechanisms.

**Human Brain Development and Organoid Models**

Compared to other primates, the human brain is both larger and more complex and develops differently. Cortical neurons derive from radial glial cells (RGCs, also known as ventral or apical RGCs), which directly contact the lateral ventricle and have long processes that extend to the pial surface. These RGCs give rise to cortical neurons directly or through intermediate progenitor cells (IPCs). In human, RGCs also differentiate into outer radial glial cells (oRGCs, also known as basal RGCs) which lack apical contacts with the lateral ventricle, as their cell bodies translocate into the outer subventricular zone but retain basal contacts with the pial surface. These oRGCs are considered key factors for the human cortical surface’s increased size and complexity. Daughter cells derived from RGCs migrate away from the ventricle toward the cortical plate, where they give rise to differentiated neurons. Deep-layer neurons form first, and upper-layer neurons emerge later during development, in an inside-out manner (Figure 1A). Once in their final destination, cortical excitatory neurons mature and are classified based on their laminar position, gene expression profile, and projection type. Later during development, RGCs also produce astrocytes and oligodendrocytes. In addition, inhibitory interneurons integrate into the cortical circuit. These interneurons are generated in the ganglionic eminences (ventral forebrain) and migrate tangentially toward the cortex (dorsal forebrain; Figure 1B). It has been proposed that a small proportion of interneurons can also be produced locally in the cortex in humans. Different types of inhibitory neurons have been described in the cortex according to their morphology, origin, location, gene expression, and electrophysiological properties. Moreover, specific interneuron subtypes can be observed only in humans. Many of these aspects of brain development can be recapitulated in organoids. To date, 2 general types of 3D organoids have been described: whole-brain organoids, also called cerebral organoids, or directed regional brain organoids. Formation of cerebral organoids relies on the intrinsic capacity of PSCs to self-pattern and self-organize. Cerebral organoids have the potential to manifest different brain regions in a single organoid (ie, cortex, hippocampus, retina), allowing the study of cell–cell interactions within these brain regions but they can be heterogeneous from batch to batch. On the other hand, formation of directed regional brain organoids employs small molecules and growth factors to promote neural induction (typically through inhibition of the bone morphogenetic protein [BMP]/transforming growth factor-beta [TGF-β] signaling pathways) and to specify region identity such as human cortical organoids or human cortical spheroids (hCSs), human ventral organoids or human subpallium spheroids (hSSs), among others. In addition, cellular interactions between these brain regions can be analyzed by merging 2 types of region-specified organoids, for example, fusing hCS and hSS to observe tangential migration of interneurons from the ganglionic eminences to the cortex. Some of the organoid protocols require the use of Matrigel, a gelatinous protein mixture resembling the extracellular matrix, to promote cell differentiation. Both types of organoids form similar ventricular zone-like structures surrounded by RGCs and IPCs, which give rise to cortical neurons in a time- and space-dependent pattern (Figure 1), and they resemble human brain tissue at the molecular, cellular, and electrophysiological levels. However, their organization is rudimentary. Although neurons of the 6 cortical layers are present, deep-layer neurons are formed first and are located around ventricular zone-like structures, while upper-layer neurons appear later more externally without a clear layer definition. Interestingly, they contain human-specific features, such as increased cortical thickness and the presence of oRGCs. Despite their limitations, organoids are an ideal platform to study human diseases that affect brain development.

**Organoid Models for Developmental Epilepsies**

**Tuberous Sclerosis**

Tuberous sclerosis complex (TSC) is a developmental disorder characterized by the presence of benign tumors in multiple organs, including the brain. These brain tumors, called cortical tubers, manifest as an accumulation of enlarged and dysplastic neurons and glia in the cortex. A high percentage of patients with TSC have epilepsy, autism, and intellectual disability. Tuberous sclerosis complex is caused by loss-of-function mutations in the TSC1 or TSC2 genes, which encode the proteins hamartin (TSC1) and tuberin (TSC2). These proteins, joined with TBC1D7, form a complex which represses mammalian target of rapamycin complex 1 (mTORC1) signaling. Blair et al used CRISPR-Cas9 gene editing to insert loss-of-function mutations in TSC1 and TSC2 human embryonic stem cells (hESCs) to model TSC in vitro. They showed that homozygous hESCs, but not heterozygous, exhibited an increase in mTORC1 signaling and a reduction in AKT phosphorylation. Further, they differentiated hESCs to hCSs to study the role of TSC during brain development. While they did not find significant differences in the number of progenitor or proliferative cells, they observed a reduction or delay of neuronal markers and an increase of glial cells in TSC1−/− and TSC2−/− hCS. Neurons and glia were enlarged and dysmorphic in hCS derived from homozygous cells, resembling cells found in cortical tubers in patients. The model also provided support for the hypothesis that in heterozygous patients, cytomegalic cells appear after a somatic second mutation (known as second-hit model) that results in the biallelic inactivation of TSC1 or TSC2. To test this hypothesis, the authors developed an hESC line with a constitutive loss-of-function mutation in 1 allele of the TSC2 gene and a Cre-inducible conditional mutation in the second allele (TSC2Δ/Δ).
Conditional hESCs were differentiated into hCS, and Cre was added after 12 days in vitro during the progenitor expansion phase. Cells with the second-hit mutation became dysmorphic and were bigger, similar to the cells found in homozygous TSC1/C0/C0 and TSC2/C0/C0 hCS. Finally, they showed that chronic rapamycin treatment prevented the cellular hypertrophy. A tuber-like phenotype was found in another preliminary study by Eichmüller and colleagues using cerebral organoids derived from TSC patient iPSCs with heterozygous mutations in TSC2. In this study, the researchers also identified a new type of cell, the caudal late interneuron progenitors or CLIP cells, in TSC organoids by single-cell RNA sequencing. The CLIP cells differentiated into interneurons and expressed high level of epidermal growth factor receptor (EGFR). The first study provided evidence supporting that a second mutation is needed for the formation of cortical tubers. However, in the second study, the authors observed tuber-like structures even with only 1 allele mutated in TSC2 gene. Further analysis would be critical.
to corroborate the second-hit model. For this reason, it is essential to use isogenic controls and compare multiple iPSC lines to obtain consistent data. Although organoids contain cells that resemble those found in patients with TSC, they do not recapitulate focal tuber-like abnormalities. These studies also point to the mTORC1 signaling pathway as a potential therapeutic target for patients with TSC to prevent the formation of cortical tubers.

**Rett Syndrome**

Rett syndrome (RTT) is a neurodevelopmental disorder produced by mutations in the X-linked methyl-CpG-binding protein 2 (MeCP2) gene. Most patients with RTT are female, with intellectual disability, motor coordination problems, seizures, autism, and respiratory and cardiac abnormalities. Mellios et al analyzed cerebral organoids from a patient having RTT with a frameshift mutation in the MeCP2 gene resulting in a premature stop codon. These organoids showed an increase in ventricular area and a thinning of the ventricular wall. Moreover, patient organoids showed an increase in RGCs and neuronal cells, but a reduction in IPCs. The researchers also found that mutations in MeCP2 produced an upregulation of miR-199 and miR-214 and an increase in BMP levels. They also analyzed radial migration of cortical progenitor cells by electroporating MeCP2 short hairpin RNA expressing green fluorescent protein (GFP) in control organoids or GFP control vector in mutant organoids and found a migration reduction in both cases. This study identified novel microRNAs which regulate the MeCP2 pathway and affect early cortical development. However, it is unknown how these earlier effects on the RGCs and IPCs contribute to the epileptogenesis. A complete understanding of the MeCP2 downstream pathway would be necessary to develop better treatments for patients with RTT.

**Periventricular Heterotopia**

Cerebral organoids have also been used to model periventricular heterotopia (PH), a group of heterogeneous disorders characterized by intellectual disability and epilepsy. One study used iPSCs from 2 patients, 1 with a heterozygous mutation in the FAT atypical cadherin 4 (FAT4) gene and the other with homozygous mutations in the dachshous cadherin-related 1 (DCHS1) gene, and performed gene editing with CRISPR-Cas9 to create KO lines for both genes. They found accumulation of neurons in ventricular zones in organoids derived from all lines, which could be due to an aberrant morphology of RGCs and defective radial migration. The researchers also identified changes in the expression of genes involved in the formation of the cytoskeleton and cell junction and axon guidance. In another study, the same group examined the role of endothelin-converting enzyme 2 (ECE2) gene where 2 biallelic variants have been identified in patients with PH. They found that chronic enzymatic inhibition of ECE2 using PHOS and CRISPR/Cas9-mediated KO of ECE2 in cerebral organoids promoted an increase of neural progenitor cells and a reduction of neurons. They also described changes in the microtubule, actin cytoskeleton, and polarity of RGCs, as well as in the production of extracellular matrix proteins and their receptors. Similar ectopic neuronal positioning in ventricular zones described in the first study was found in another research in control cerebral organoids after overexpression of the pleckstrin homology domain containing family G member 6 gene, which encodes the guanine nucleotide exchange factor and was found mutated in a PH patient. These studies have been able to recapitulate PH phenotypes which were only partially observed in mouse models and highlight the use of PSC-derived organoids to study PH disorders. They also identified microtubule and cytoskeleton proteins as key players to maintain RGC morphology and promote correct neuronal radial migration. Targeting cytoskeleton components might be useful to prevent migration defects in patients with PH.

**Angelman Syndrome**

Angelman syndrome (AS) is a neurodevelopmental disorder characterized by delayed development, intellectual disability, and seizures. Most AS cases are caused by a loss-of function mutation of the ubiquitin protein ligase E3A (UBE3A) gene, which encodes a HECTE3 ubiquitin ligase. Using gene-edited KO ESCs and iPSCs derived from 1 patient with AS, Sun et al found that pyramidal-shaped neurons in AS hCS exhibited augmented excitability and fast components of afterhyperpolarization due to elevated levels of calcium- and voltage-dependent big potassium (BK) channels. Moreover, using Ca$^{2+}$ imaging and perforated patch recordings, they observed that UBE3A loss promoted neuronal hyperactivity and synchronization. These results suggest that the inhibition of BK channels might reduce the hyperactivity in patients with AS and control seizure development. This study is also the first to observe hyperactivity in organoids derived from patients with epilepsy as a proof of concept that organoids could be used to study disruption in neuronal networks. However, it is unclear whether this hyperactivity leads to the development of seizures.

**Miller-Dieker syndrome**

Miller-Dieker syndrome (MDS) is a severe form of lissencephaly associated with mental retardation and epilepsy, and microcephaly in some patients. Miller-Dieker syndrome is caused by large heterozygous deletions in chromosome 17. This region contains dozens of genes, including PFAH1B1 (LIIS1 protein) and YWHAE (14-3-3ζ protein). Using cortical organoids derived from MDS iPSCs, Bershteyn et al showed an increase of apoptosis in the VZ-like region and horizontal division in RGCs, as well as a decrease in the size of organoids. They also found migration defects of doublecortin+ cells after organoids were embedded in Matrigel. Miller-Dieker syndrome organoids showed an increase in deep-layer neurons, without a major change in the laminar distribution. The
Developmental Epileptic Encephalopathies

Developmental epileptic encephalopathies are severe disorders characterized by intractable epileptic seizures and developmental delay. In 1 study, researchers analyzed 36 cases from 25 families with epileptic encephalopathies and found germline recessive mutations in the UDP-Glucose 6-Dehydrogenase (UGDH) gene. The UGDH encodes an oxidoreductase that converts UDP-glucose to UDP-glucuronic acid, a key component of proteoglycans and glycolipids. The authors generated cerebral organoids from several patients with 2 different heterozygous mutations and 1 homozygous mutation in the UGDH gene. After 10 weeks in vitro, mutant organoids were significantly smaller and showed a decrease in neuronal progenitor markers and in the number of proliferative cells. However, the authors did not find these defects in UGDH mutant zebrafish. This study brings evidence that extracellular matrix components are critical during brain development and opens up a line of investigation using dietary supplements or modulators of UGDH activity to regulate seizure formation in patients with UGDH mutations.

Progressive Myoclonus Epilepsy

Myoclonic epilepsy of Unverricht and Lundborg or epilepsy, progressive myoclonus 1 (EPM1) is an autosomal recessive disorder and the most common form of progressive myoclonus epilepsy (PME). Patients with PME often present with a combination of myoclonus, epilepsy, and progressive neurological deterioration, and many have mutations in the cystatin B (CSTB) gene and its promoter. To study the role of CSTB during human brain development, Di Matteo et al used cerebral organoids derived from patients with EPM1 and healthy controls. They showed that overexpression of CSTB in control organoids promoted cell proliferation, while overexpression of a mutant form of CSTB inhibited it. Similarly, organoids derived from EPM1 patients were smaller and showed a decrease in cell proliferation, but an increase in the number of neurons. In line with a previous study that reported CSTB in synaptosomes, CSTB was detected in the media of organoid cultures. Interestingly, control organoids showed a decrease in cell proliferation after being cultured with media from EPM1 mutant organoids, whereas media from control organoids rescued the proliferation defect in EPM1 organoids. The researchers observed a disruption in interneuron migration when ventral organoids were fused to dorsal organoids derived from EPM1 patients. Taken together, these studies indicate that the maintenance of CSTB levels is critical for proper cell proliferation and interneuron migration during brain development. Future studies are needed to explore the use of CSTB supplements to prevent or partially correct these defects in patients with PME.

Other Cortical Malformations

Microcephaly due to loss-of-function mutations in the CDK5RAP2 gene, or to ZIKA virus infection, has also been modeled using organoids. These studies reported smaller organoids, due to a decrease in cell proliferation and/or increase in cell death. On the other hand, macrocephaly has been studied in organoids by CRISPR/Cas9-mediated phosphatase and tensin homolog (PTEN) deletion in hESCs. The PTEN heterozygous loss-of-function mutations have been associated with human macrocephaly. The PTEN mutant organoids were larger and exhibited more folding due to an increase in progenitor and oRGC proliferation and in transient neuronal
differentiation. Interestingly, mouse PTEN mutant organoids did not show increased folding, suggesting a human-specific phenotype. These studies provide new insights into the mechanisms that control the structure of human brain and highlight the use of human organoids to analyze human characteristics like increased cortical lamination and folding which cannot be studied using animal models with smooth brains like mice.

**Limitations, Challenges, and Future Directions**

Since 2013, when brain organoid technology was first described, several studies have demonstrated its ability to recapitulate certain features of the developing human brain. By revealing phenotypes at the level of molecules, cells, and networks (Figure 2), these organoid models may be useful for studying disease mechanisms underlying neurodevelopmental disorders such as epilepsy. Nevertheless, these models also have their limitations. One of the challenges of organoid systems is the variability between organoids from independent experiments or from different cell lines, especially in whole-brain organoids.\(^{33,70}\) Moreover, organoids are frequently immature and resemble the developing brain only up to early-to-mid gestation. It has been difficult to recapitulate postnatal or adult stages because of the relative immaturity of the neurons and circuitry in the organoids. In addition, organoids lack specific neuronal subtypes which appear later during development, that is, parvalbumin and somatostatin interneurons; these cell types are relevant to accurately model disease phenotypes. Deep- and upper-layer neurons are present in organoids and are segregated spatially, but they do not show the clear 6-layer lamination found in vivo. Moreover, the formation of gyrus and sulcus has been observed after overexpression of PTEN, but the folding capacity in control organoids is limited. It is also important to note that organoids contain ventricular-like structures. Although these ventricular regions mimic some features of the human brain, organoids are not organized in specialized areas like the brain, making the overall organoid structure different from the human brain. In addition, organoids lack the vasculature, and the limited oxygenation in their core causes stress and cell death inside the organoids.\(^{71}\) Organoids also lack cells of non-neural origin, such as microglia, particularly in patterned organoids. Organoids have been very useful to study cellular phenotypes related to epilepsy.
However, a key aspect of epilepsy, the development of seizures, and how electrophysiological properties of the brain can be recapitulated in organoids, is still an ongoing area of research. Overcoming these limitations will allow more accurate models of disease pathology. For example, the recent creation of blood–brain barrier organoids has opened up new avenues for characterizing phenotypes relevant to Alzheimer disease. In coming years, better organoid protocols, based on a better understanding of human brain development, will be critical for opening new avenues of research. We have no doubt that although the organoid field is still young, these exciting models will accelerate our knowledge of human brain development and lead to new strategies for treating epilepsy.

Acknowledgments

Figure illustrations were constructed using BioRender and Adobe Illustrator. We are grateful for support from the Robert J. Kleberg Jr and Helen C. Kleberg Foundation and the Semmes Foundation, Inc.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the National Institute of Health (R01NS093992, R01NS113516, R01NS089770, and R21AG066496 to J.H.) and from postdoctoral fellowships from the Lennox-Gastaut Syndrome Foundation and the American Epilepsy Society to V. N.-E.

ORCID iD

Jenny Hsieh  https://orcid.org/0000-0003-0214-0771

References

1. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015;5(6): a022426. doi:10.1101/cshperspect.a022426
2. Manford M. Recent advances in epilepsy. J Neurol. 2017;264(4):1811-1824. doi:10.1007/s00415-017-8394-2
3. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE). Epilepsia. 2005;46(4):470-472. doi:10.1111/j.0013-9580.2005.66104.x
4. Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(31):821-825. doi:10.15585/mmwr.mm6631a1
5. Fink JI, Robinson TM, Germain ND, et al. Disrupted neuronal maturation in Angelman syndrome-derived induced pluripotent stem cells. Nat Commun. 2017;8:15038. doi:10.1038/ncomms15038
6. Higurashi N, Uchida T, Lossin C, et al. A human Dravet syndrome model from patient induced pluripotent stem cells. Mol Brain. 2013;6:19. doi:10.1186/1756-6606-6-19
7. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-1147. doi:10.1126/science.282.5391.1145
8. Takehashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. doi:10.1016/j.cell.2006.07.024
9. Maroof AM, Keros S, Tyson JA, et al. Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell. 2013;12(5):559-572. doi:10.1016/j.stem.2013.04.008
10. Chiallagnarn T, Trujillo CA, Freitas BC, et al. A human neurodevelopmental model for Williams syndrome. Nature. 2016;536(7616):338-343. doi:10.1038/nature19067
11. Shi Y, Kirwan P, Livey SJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc. 2012;7(10):1836-1846. doi:10.1038/nprot.2012.116
12. Lybrand ZR, Goswami S, Hsieh J. Stem cells: a path towards improved epilepsy therapies. Neuropharmacology. 2020;168:107781. doi:10.1016/j.neuropharm.2019.107781
13. Niu W, Parent JM. Modeling genetic epilepsies in a dish. Dev Dyn. 2020;249(1):56-75. doi:10.1002/dvdy.79
14. Ben Jehuda R, Shemer Y, Binah O. Genome editing in induced pluripotent stem cells using CRISPR/Cas9. Stem Cell Rev Rep. 2018;14(3):323-336. doi:10.1007/s12015-018-9811-3
15. Kwan KY, Sestan N, Anton ES. Transcriptional co-regulation defines cortical circuits, and intellectual creativity. Cold Spring Harb Perspect Med. 2015;5(6):a022426. doi:10.1101/cshperspect.a022426
16. Defelipe J. The evolution of the brain, the human nature of cortical circuits, and intellectual creativity. Front Neuroanat. 2011;5:29. doi:10.3389/fnana.2011.00029
17. Noctor SC, Flint AC, Weissman TA, Dammerman RS, Kriegstein AR. Neurons derived from radial glial cells establish radial units in neocortex. Nature. 2001;409(6821):714-720. doi:10.1038/35055553
18. Di Lullo E, Kriegstein AR. The use of brain organoids to investigate neural development and disease. Nat Rev Neurosci. 2017;18(10):573-584. doi:10.1038/nrn.2017.107
19. Kwan KY, Sestan N, Anton ES. Transcriptional co-regulation of neuronal migration and laminar identity in the neocortex. Development. 2012;139(9):1535-1546. doi:10.1242/dev.069963
20. Kwan KY, Sestan N, Anton ES. Transcriptional co-regulation of neuronal migration and laminar identity in the neocortex. Development. 2012;139(9):1535-1546. doi:10.1242/dev.069963
21. Hansen DV, Lui JH, Parker PR, Kriegstein AR. Neurogenic radial glia in the outer subventricular zone of human neocortex. Nature. 2010;464:554-561. doi:10.1038/nature08845
22. Cadwell CR, Bhduri A, Mostajo-Radji MA, Keefe MG, Nowakowski TJ. Development and arealization of the cerebral cortex.
37. Bagley JA, Reumann D, Bian S, Levi-Strauss J, Knoblich JA. Fused cerebral organoids model interactions between brain regions. *Nat Methods.* 2017;14(7):743-751. doi:10.1038/nmeth.4304

38. Birey F, Andersen J, Makinson CD, et al. Assembly of functionally integrated human forebrain spheroids. *Nature.* 2017;545(7652):54-59. doi:10.1038/nature22330

39. Xiang Y, Tanaka Y, Patterson B, et al. Fusion of regionally specified HPSC-derived organoids models human brain development and interneuron migration. *Cell Stem Cell.* 2017;21(3):383-398. e7. doi:10.1016/j.stem.2017.07.007

40. Trujillo CA, Gao R, Negraes PD, et al. Complex oscillatory waves emerging from cortical organoids model early human brain network development. *Cell Stem Cell.* 2019;25(4):558-569.e7. doi:10.1016/j.stem.2019.08.002

41. Camp JG, Badsha F, Florio M, et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. *Proc Natl Acad Sci U S A.* 2015;112(51):15672-15677. doi:10.1073/pnas.1520760112

42. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell.* 1993;75(7):1305-1315. doi:10.1016/0092-8674(93)90618-z

43. van Slegtenhorst M, De Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. *Science.* 1997;277(5327):805-808. doi:10.1126/science.277.5327.805

44. Curatolo P, Moavero R, De Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. *Lancet Neurol.* 2015;14(7):733-745. doi:10.1016/S1474-4422(15)00069-1

45. Blair JD, Bateup HS. New frontiers in modeling tuberous sclerosis with human stem cell-derived neurons and brain organoids. *Dev Dyn.* 2020;249(1):46-55. doi:10.1002/dvdy.60

46. Blair JD, Hockemeyer D, Bateup HS. Genetically engineered human cortical spheroid models of tuberous sclerosis. *Nat Med.* 2018;24(10):1568-1578. doi:10.1038/s41591-018-0139-y

47. Eichmüller OL, Corsini NS, Vértes É, et al. Cerebral organoid model reveals excessive proliferation of human caudal telencephalon interneuron progenitors in tuberous sclerosis complex. *Biorxiv.* 2020. doi:10.1101/2020.02.27.967802

48. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet.* 1999;23(2):185-188. doi:10.1038/13810

49. Neul JL, Zoghbi HY. Rett syndrome: a prototypical neurodevelopmental disorder. *Neuroscientist.* 2004;10(2):118-128. doi:10.1177/1073858403260995

50. Mellios N, Feldman DA, Sheridan SD, et al. MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling. *Mol Psychiatry.* 2018;23(4):1051-1065. doi:10.1038/mp.2017.86

51. Cardoso C, Boys A, Parrini E, et al. Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. *Neurology.* 2009;72(9):784-792. doi:10.1212/01.wnl.000036339.08878.2d

52. Klaus J, Kanton S, Kyrousi C, et al. Altered neuronal migratory trajectories in human cerebral organoids derived from individuals with neuronal heterotopia. *Nat Med.* 2019;25(4):561-568. doi:10.1038/s41591-019-0371-0
53. Buchsbaum IY, Kielkowski P, Giorgio G, et al. ECE2 regulates neurogenesis and neuronal migration during human cortical development. *EMBO Rep*. 2020;21(5):e48204. doi:10.15252/embr.201948204

54. O’Neill AC, Kyrousi C, Klaus J, et al. A primate-specific isoform of PLEKHG6 regulates neurogenesis and neuronal migration. *Cell Rep*. 2018;25(10):2729-2741. e6. doi:10.1016/j.celrep.2018.11.029

55. Buiting K, Williams C, Horsthemke B. Angelman syndrome - insights into a rare neurogenetic disorder. *Nat Rev Neurol*. 2016;12(10):584-593. doi:10.1038/nrneurol.2016.133

56. Mabb AM, Judson MC, Zylka MJ, Philpot BD. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. *Trends Neurosci*. 2011;34(6):293-303. doi:10.1016/j.tins.2011.04.001

57. Sun AX, Yuan Q, Fukuda M, et al. Potassium channel dysfunction in human neuronal models of Angelman syndrome. *Science*. 2019;366(6472):1486-1492. doi:10.1126/science.aav5386

58. Dobyns WB, Stratton RF, Parke JT, Greenberg F, Nussbaum RL, Ledbetter DH. Miller-Dieker syndrome: lissencephaly and monosomy 17p. *J Pediatr*. 1983;102(4):552-558. doi:10.1016/s0022-3476(83)80183-8

59. Bershteyn M, Nowakowski TJ, Pollen AA, et al. Human iPSC-derived cerebral organoids model cellular features of lissencephaly and reveal prolonged mitosis of outer radial glia. *Cell Stem Cell*. 2017;20(4):435-449.e4. doi:10.1016/j.stem.2016.12.007

60. Lefremova V, Manikakis G, Krefft O, et al. An organoid-based model of cortical development identifies non-cell-autonomous defects in WNT signaling contributing to Miller-Dieker syndrome. *Cell Rep*. 2017;19(1):50-59. doi:10.1016/j.celrep.2017.03.047

61. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell*. 2004;119(1):19-31. doi:10.1016/j.cell.2004.09.011

62. Hengel H, Bosso-Lefevre C, Grady G, et al. Loss-of-function mutations in UDP-Glucose 6-Dehydrogenase cause recessive developmental epileptic encephalopathy. *Nat Commun*. 2020;11(1):595. doi:10.1038/s41467-020-14360-7

63. Berkovic SF, Andermann F, Carpenter S, Wolfe LS. Progressive myoclonus epilepsies: specific causes and diagnosis. *N Engl J Med*. 1986;315(5):296-305. doi:10.1056/NEJM198607313150506

64. Canafoglia L, Gennaro E, Capovilla G, et al. Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations. *Epilepsia*. 2012;53(1):2120-2127. doi:10.1111/j.1528-1167.2012.03718.x

65. Di Matteo F, Pipicelli F, Kyrousi C, et al. Cystatin B is essential for proliferation and interneuron migration in individuals with EPM1 epilepsy. *EMBO Mol Med*. 2020;12(6):e11419. doi:10.15252/emmm.201911419

66. Penna E, Cerciello A, Chambery A, et al. Cystatin B involvement in synapse physiology of rodent brains and human cerebral organoids. *Front Mol Neurosci*. 2019;12:195. doi:10.3389/fnmol.2019.00195

67. Garcez PP, Loiola EC, Madeiro da Costa R, et al. Zika virus impairs growth in human neurospheres and brain organoids. *Science*. 2016;352(6287):816-818. doi:10.1126/science.aaf6116

68. Watanabe M, Buth JE, Vishlaghi N, et al. Self-organized cerebral organoids with human-specific features predict effective drugs to combat Zika virus infection. *Cell Rep*. 2017;21(2):517-532. doi:10.1016/j.celrep.2017.09.047

69. Li Y, Muffat J, Omer A, et al. Induction of expansion and folding in human cerebral organoids. *Cell Stem Cell*. 2017;20(3):385-396.e3. doi:10.1016/j.stem.2016.11.017

70. Velasco S, Kedaigle AJ, Simmons SK, et al. Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. *Nature*. 2019;570(7762):523-527. doi:10.1038/s41586-019-1289-x

71. Bhaduri A, Andrews MG, Mancia Leon W, et al. Cell stress in cortical organoids impairs molecular subtype specification. *Nature*. 2020;578(7793):142-148. doi:10.1038/s41586-020-1962-0

72. Blanchard JW, Bula M, Davila-Velderrain J, et al. Reconstruction of the human blood-brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes. *Nat Med*. 2020;26:952-963. doi:10.1038/s41591-020-0886-4